Phastar to Provide Pro Bono Aid to Medicines Development for Global Health
Support to focus on two double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire.
Phastar, a biometrics contract research organization (CRO), announced that it will be providing pro bono support to Medicines Development for Global Health (MDGH), a nonprofit focused on the development of medicines for neglected diseases primarily affecting people living in low- and middle-income countries. As part of Phastar’s assistance, MDGH will have access to the company’s biometrics experts during two large double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire. According to a company release, one trial will be focused on evaluating the safety of moxidectin and the second is evaluating repeat single dosing compared with ivermectin in individuals living in onchocerciasis (river blindness) endemic areas.
At Phastar, we have the expertise and the resources to make a meaningful difference and to deliver on our mission to improve human health. As a B Corp organization, we strive to be a force for good, and one of our strategic objectives is to lead the CRO industry in corporate social responsibility,” said Graham Clark, CEO, Phastar. “The Phastar Cares Scheme, which offers free access to our statisticians, data scientists, data managers, and programmers, is an important part of that commitment. We are proud to be in a position to help MDGH on their mission to eradicate onchocerciasis.”
Reference: Phastar Offers Pro Bono Support to Medicines Development for Global Health. Phastar. October 26, 2023. Accessed October 27, 2023. https://phastar.com/resources/news/318-phastar-offers-pro-bono-support-to-medicines-development-for-global-health
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
